Abbvie Stemcentrx LLC

Stemcentrx, Inc.

Amgen Fremont Inc.

Trellis Bioscience, Inc.

Amgen Inc.

Adicet Therapeutics, Inc.

Astrazeneca Ab

Adicet Bio, Inc.

Trellis Rsv Holdings, Inc.

Other

Celldex Therapeutics Limited

Abgenix, Inc.

U3 Pharma Gmbh

Curagen Corporation

Orit Foord

Robert A Stull

Scott J Dylla

David Y Liu

Michael Torgov

Laura Saunders

Hui Shao

Scott L Klakamp

Bruce Alan Keyt

Jaspal Singh Kang

Palaniswami Rathanaswami

Larry L Green

Jean M Gudas

Ian Nevin Foltz

Xiao Feng

Qiaojuan Jane Su

Xiao-Chi Jia

Lawrence M Kauvar

Chadwick Terence King

Ying Liu

Xiao Dong Yang

Richard F Weber

Robert Raya

Jose Corvalan

Aya Jakobovits

Meina Liang

Giorgio Senaldi

Ellen J Collarini

Raffaella Faggioni

Gizette Sperinde

Mary Haak-Frendscho

Marianne Theresa Santaguida

Alex Bankovich

Kiran Ahluwalia

Johannes Hampl

Kathy Manchulenko

Daulet Kadyl Satpayev

Andy An-deh Lin

Jeffrey Traer Bernstein

John Stephen Babcook

Krista Maureen McCutcheon

Fen Zhang

Alexandra Leida Liana Lazetic

Ying-Ping Jiang

William Usinger

Minha Park

Bo Chen

Stote Ellsworth

Monette Aujay

Marjan Fatholahi

Hung Nguyen

Yifeng Frank Jing

Sunil Bhakta

Radhika Chetan Desai

Yen-Wah Lee

Wade C Anderson

Jose R F Corvalan

Craig Pigott

Amy K Schneider

Yan Li

Saiyou Ohshima

Scott Klakamp

Mike Rothe

Henri Lichenstein

Yoram Reiter

Peter S Mezes

Eric Borges

Luca Rastelli

Thore Hettmann

Ilan Beer

Michael Jeffers

John L Herrmann

William LaRochelle

William J Larochelle

Esther Zwick-Wallasch

Galit Denkberg

Yael Teboul (Elbaz)

Kam Fai Tse

Yael Shperber (Sery)

Reut Erel Segal

Ravit Oren

Dror Shmuel Alishekevitz

Juan Davagnino

Mira Peled Kamar

Keren Sinik

Feng Xiao

Vincent A Pollack

Gulshan Ara

Andrei Chapoval

Cyrus Karkaria

Norbert Prenzel

Matthew Ian Hoopes

Jason Michael Romero

Mary Michael Brody

Paul Anthony Escarpe

Krista Maureen Mccutcheon

Rozanne Lee

Meina L Liang

The present invention relates to engineered γδ T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered γδ T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered γδ T-cell(s) populations to therapeutically useful quantities. An engineered γδ T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.

Engineered γδ T-cells

The present invention relates to methods for the selective expansion of γδ T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched γδ T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.

Methods for selective expansion of gamma delta t-cell populations and compositions thereof

The present application is directed to agents that bind an epitope specific to a δ3 γδ TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand or selectively expand δ3 γδ T cells. Also described herein are methods of using expanded δ3 γδ T cells for treatment of a subject in need thereof.

Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof

The present invention relates to methods for the selective expansion of &#x3b3;&#x3b4; T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched &#x3b3;&#x3b4; T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.

Methods for selective expansion of &#x3b3;&#x3b4; T-cell populations and compositions thereof

The present invention relates to engineered &#x3b3;&#x3b4; T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered &#x3b3;&#x3b4; T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered &#x3b3;&#x3b4; T-cell(s) populations to therapeutically useful quantities. An engineered &#x3b3;&#x3b4; T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.

Engineered &#x3b3;&#x3b4; T-cells

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Light chain variable regions

Anti-PTK7 modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.

Anti-PTK7 antibodies and methods of use

Provided are novel seizure related 6 (SEZ6) modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders.

Anti SEZ6 antibodies and methods of use

Anti-DLL3 antibody drug conjugates for treating cancer

Anti-CD324 monoclonal antibodies and uses thereof

Provided herein are anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.

Anti-claudin antibodies and methods of use

Growing community of inventors

Foster City, CA, United States of America

Orit Foord